Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code: 600276) issued an announcement regarding the postponement of its ninth session Board of Directors re-election. According to the official document, the term of the ninth session expired on February 1, 2026, but the re-election process is still in preparation.

In order to ensure continuity and stability, the company has extended the terms of the current directors, relevant committees, and senior management. They will continue to perform their respective duties in compliance with applicable laws and the articles of association until the new Board is elected.

The announcement confirms that this postponement will not affect the company’s normal operations. The re-election procedure is being processed, and relevant disclosures will be made once completed.